Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. News
Oct 27, 2025 - globenewswire.com
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
Oct 22, 2025 - zacks.com
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
ORIC Pharmaceuticals, Inc. Quantitative Score
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
ORIC Pharmaceuticals, Inc. Financials
Table Compare
Compare ORIC metrics with: | |||
|---|---|---|---|
Earnings & Growth | ORIC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ORIC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ORIC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ORIC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
ORIC Pharmaceuticals, Inc. Income
ORIC Pharmaceuticals, Inc. Balance Sheet
ORIC Pharmaceuticals, Inc. Cash Flow
ORIC Pharmaceuticals, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
ORIC Pharmaceuticals, Inc. Executives
| Name | Role |
|---|---|
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer & Director |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board |
| Dr. Edna Chow Maneval Ph.D. | Executive Vice President of Clinical Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Jacob M. Chacko M.B.A., M.D. | President, Chief Executive Officer & Director | 1979 | 1.04M | |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer | 1967 | 735.59K | |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer | Male | 1975 | 684.16K |
| Dr. Richard A. Heyman Ph.D. | Co-Founder, Independent Chairman & Member of Scientific Advisory Board | 1957 | 100K | |
| Dr. Edna Chow Maneval Ph.D. | Executive Vice President of Clinical Development | 1961 | -- |
ORIC Pharmaceuticals, Inc. Insider Trades
| Date | 6 Oct |
| Name | Piscitelli Dominic |
| Role | Chief Financial Officer |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 11000 |
| Date | 6 Oct |
| Name | Piscitelli Dominic |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 11000 |
| Date | 6 Oct |
| Name | Piscitelli Dominic |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 11000 |
| Date | 6 Oct |
| Name | Chacko Jacob |
| Role | PRESIDENT AND CEO |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 37461 |
| Date | 3 Oct |
| Name | Heyman Richard A. |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 31353 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 6 Oct | Piscitelli Dominic | Chief Financial Officer | Acquired | M-Exempt | 11000 |
| 6 Oct | Piscitelli Dominic | Chief Financial Officer | Disposed | S-Sale | 11000 |
| 6 Oct | Piscitelli Dominic | Chief Financial Officer | Disposed | M-Exempt | 11000 |
| 6 Oct | Chacko Jacob | PRESIDENT AND CEO | Disposed | S-Sale | 37461 |
| 3 Oct | Heyman Richard A. | Director | Acquired | M-Exempt | 31353 |